NCT02856568View on ClinicalTrials.gov

Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 1, 2017

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2021

Conditions
Non-Resectable CholangiocarcinomaRecurrent CholangiocarcinomaStage III Extrahepatic Bile Duct CancerStage III Intrahepatic CholangiocarcinomaStage IIIA Hilar CholangiocarcinomaStage IIIB Hilar CholangiocarcinomaStage IVA Extrahepatic Bile Duct CancerStage IVA Hilar CholangiocarcinomaStage IVA Intrahepatic CholangiocarcinomaStage IVB Extrahepatic Bile Duct CancerStage IVB Hilar CholangiocarcinomaStage IVB Intrahepatic CholangiocarcinomaUnresectable Extrahepatic Bile Duct Carcinoma
Interventions
DRUG

Cisplatin

Given IV

DRUG

Gemcitabine Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Ricolinostat

Given PO

Trial Locations (3)

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT02856568 - Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma | Biotech Hunter | Biotech Hunter